The perinucleolar compartment: structure, function, and utility in anti-cancer drug development

Eugene V. Makeyev, Sui Huang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


The perinucleolar compartment (PNC) was initially identified as a nuclear structure enriched for the polypyrimidine tract-binding protein. Since then, the PNC has been implicated in carcinogenesis. The prevalence of this compartment is positively correlated with disease progression in various types of cancer, and its expression in primary tumors is linked to worse patient outcomes. Using the PNC as a surrogate marker for anti-cancer drug efficacy has led to the development of a clinical candidate for anti-metastasis therapies. The PNC is a multicomponent nuclear body situated at the periphery of the nucleolus. Thus far, several non-coding RNAs and RNA-binding proteins have been identified as the PNC components. Here, we summarize the current understanding of the structure and function of the PNC, as well as its recurrent links to cancer progression and metastasis.

Original languageEnglish
Article number2306777
Issue number1
Early online date27 Jan 2024
Publication statusE-pub ahead of print - 27 Jan 2024


  • Anti-cancer drug development
  • non-coding RNA
  • nucleolus
  • PNC
  • RNA binding proteins


Dive into the research topics of 'The perinucleolar compartment: structure, function, and utility in anti-cancer drug development'. Together they form a unique fingerprint.

Cite this